Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
12 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Adagene Inc.’s names, not what it holds today.
Patents granted
12
12 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 3 in 2024 and 3 in 2023
Applications published
19
since 2001, to Dec 31, 2025
Names they are printed under
3
its own name, a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology6
Pharmaceuticals4
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Adagene Inc. its own name
KY, as the owner printed on each patent. 2 more under the same name are not counted (printed in CH)
15 publishedAdagene Inc. its own name
named as the applicant on its applications, in KY. 11 more under the same name are not counted (printed in SG, printed in CH, printed in GB)
3 publishedAdagene (Suzhou) Limited a subsidiary
named as the applicant on its applications, in CN
1 publishedNames not counted (1)
Adagene Inc.
Most of its patents print SG; this name counts in CN, KY. 0 granted and 8 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 23, 2025 | 12,503,693 | Integrated system for library construction, affinity binder screening and expression thereof | Biotechnology | Adagene Inc. |
| Aug 12, 2025 | 12,385,162 | Dynamic human heavy chain antibody libraries | Biotechnology | Adagene Inc. |
| Aug 5, 2025 | 12,378,319 | Anti-CD137 molecules and use thereof | Pharmaceuticals | Adagene Inc. |
| Aug 6, 2024 | 12,054,548 | Anti-PD-L1 antibodies and use thereof | Pharmaceuticals | Adagene Inc. |
| Apr 9, 2024 | 11,952,681 | Masked activatable CD137 antibodies | Organic fine chemistry | Adagene Inc. |
| Jan 2, 2024 | 11,859,003 | Method for treating cancer using anti-CD137 antibody | Pharmaceuticals | Adagene Inc. |
| Jul 4, 2023 | 11,692,036 | Anti-CTLA4 antibodies and methods of making and using the same | Biotechnology | Adagene Inc. |
| Feb 21, 2023 | 11,585,014 | Dynamic human antibody light chain libraries | Organic fine chemistry | Adagene Inc. |
| Feb 14, 2023 | 11,578,426 | Dynamic human heavy chain antibody libraries | Biotechnology | Adagene Inc. |
| Nov 1, 2022 | 11,485,977 | Methods and systems for autoinduction of protein expression | Biotechnology | Adagene Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 18, 2024 | 2024/0240358 | DYNAMIC HUMAN HEAVY CHAIN ANTIBODY LIBRARIES | Biotechnology | Adagene Inc. · patent 12,385,162 granted from it |
| Jun 27, 2024 | 2024/0209092 | COMBINATION THERAPIES FOR TREATING CANCER | Pharmaceuticals | Adagene Inc. |
| May 9, 2024 | 2024/0150749 | ACTIVATABLE ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | Organic fine chemistry | Adagene Inc. |
| May 2, 2024 | 2024/0141046 | ANTI-CTLA4 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME | Biotechnology | Adagene Inc. |
| Sep 14, 2023 | 2023/0287597 | DYNAMIC HUMAN ANTIBODY LIGHT CHAIN LIBRARIES | Organic fine chemistry | Adagene Inc. |
| Jun 29, 2023 | 2023/0203170 | Anti-CSF1R Molecules and Use Thereof | Pharmaceuticals | Adagene (Suzhou) Limited |
| Jun 30, 2022 | 2022/0204637 | ANTI-CD137 MOLECULES AND USE THEREOF | Pharmaceuticals | Adagene Inc. · patent 12,378,319 granted from it |
| Mar 24, 2022 | 2022/0090053 | INTEGRATED SYSTEM FOR LIBRARY CONSTRUCTION, AFFINITY BINDER SCREENING AND EXPRESSION THEREOF | Biotechnology | Adagene Inc. · patent 12,503,693 granted from it |
| Jul 8, 2021 | 2021/0207126 | ACTIVATABLE ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | Organic fine chemistry | Adagene Inc. · patent 11,952,681 granted from it |
| Jul 8, 2021 | 2021/0206855 | ANTI-CTLA4 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME | Biotechnology | Adagene Inc. · patent 11,692,036 granted from it |
What it applied for, 2024 to 2025: Biotechnology 2 · Organic fine chemistry 1 · Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.